Curie.Bio’s Post

We are delighted to share the outstanding performance of Ally Bridge Group, one of our top-performing fund managers in the life sciences sector, which has successfully executed its fourth liquidity event since September 2023. Specializing in late-stage private equity, Ally Bridge Group is dedicated to significant investments in groundbreaking life science innovations aimed at fulfilling critical medical needs, primarily within the U.S. MedTech, biotech, diagnostics, and telehealth industries. Our firm has consistently supported Ally Bridge's previous funds and takes pride in their recent achievements in the U.S., highlighted by four notable liquidity events within the last five months: 𝟭. 𝗖𝗚 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 [𝗖𝗚𝗢𝗡.𝗡𝗮𝘀𝗱𝗮𝗾]: Listed on January 25, 2024, this company focuses on oncolytic immunotherapy for bladder cancer. Its IPO was nearly 20 times oversubscribed, with shares initially offered at $19 and closing at $37.26 after opening at a 96% increase, valuing the company at $2.2 billion. https://lnkd.in/dkMXjz4r    𝟮. 𝗖𝗮𝗿𝗴𝗼 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 [𝗖𝗥𝗚𝗫.𝗡𝗮𝘀𝗱𝗮𝗾]: Listed in November 2023, it is a clinical-stage biotech firm developing next-generation cell therapies for cancer. The IPO price was $15.00 per share, with a recent closing at $22.01. 𝟯. 𝗥𝗮𝘆𝘇𝗲𝗯𝗶𝗼 𝗜𝗻𝗰 [𝗥𝗬𝗭𝗕.𝗡𝗮𝘀𝗱𝗮𝗾]: Listed in September 2023, specializing in targeted radiopharmaceuticals for cancer treatment, was acquired by Bristol Myers Squibb on December 26, 2023, at $62.5 per share, compared to its IPO price of $18.00. https://lnkd.in/g7bcEkiZ 𝟰. 𝗥𝗲𝗹𝗶𝗲𝘃𝗮𝗻𝘁: Invested in March 2023, this medical device company focuses on treating chronic lower back pain and was acquired by Boston Scientific on November 17, 2023. https://lnkd.in/dhjGUJAC Congratulations to all our clients who have participated in these ventures. We look forward to further deploying capital into Ally Bridge’s follow-on fund, 'ABG V'.

Latest DON Monte Carlo news. Attention all sophisticated investors. OmniSpirant Limited are delighted to announce the granting of a Venture and Innovation Award by the UK Cystic Fibrosis Trust. OmniSpirant is currently raising funds to expand and continue to develop RNA therapeutics for diseases with high unmet medical needs. Our financial model forecasts the need to raise €80M alongside our existing non-dilutive funding to reach clinical stages and generate meaningful clinical readouts for our oncology (OS003) and ARDS (OS006) programs, both of which have potential for accelerated market approval. The funding will also be used to expand our identified pipeline (4 further programs, each capable of disrupting and expanding existing multi-billion markets), and for the scalable GMP translation of our OmniSome manufacturing process. Our versatile platform can be applied to realize significant revenues from licensing deals within the investment runway. To speak with the CEO Gerry McCauley about this opportunity please book a sophisticated investor call via this link - https://lnkd.in/ejrueCpc #funding #fundingopportunity #biotech #rnatherapeutics #rna #investing

Thank you Kyle LaHucik for a brilliant share. Some additional information from FinBio deal engine: The company originally aimed to raise approximately $200 million in its initial public offering (IPO), selling 11.8 million shares at a price range of $16-$18 per share. The company specializes in developing and commercializing treatments for bladder cancer, with a focus on bladder-sparing therapies. CG Oncology's lead asset is cretostimogene grendenorepvec, an oncolytic virus immunotherapy, under development for the treatment of high-grade non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer. The therapy has received breakthrough therapy and fast-track designation from the US Food and Drug Administration for the treatment of high-risk Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC patients. The company's approach involves using an oncolytic adenovirus encoding the immunohematopoietic cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF). This candidate is designed to infect and replicate in tumor cells, directly killing them while also causing the release of tumor-derived antigens and GM-CSF to stimulate an immune response. Initially, CG Oncology has been developing this candidate as a treatment for non-muscle invasive bladder cancer. Morgan Stanley, Goldman Sachs, and Cantor Fitzgerald acted as joint book-running managers for the offering, with LifeSci Capital LLC as co-manager. The registration statements for the offering were filed with the U.S. Securities and Exchange Commission and became effective on January 24, 2024. This IPO and the development of CG Oncology's therapies reflect a growing interest and advancement in the field of oncology, particularly in developing innovative treatments for bladder cancer. #CGOncology #BiotechIPO #BladderCancerResearch #OncologyInnovation #HealthcareInvestment #Biopharmaceutical #Immunotherapy #ClinicalTrials #NASDAQ #Biotech2024 #innovation

Spoke to Cody Shandraw earlier this week about the ongoing FDA priority review for Lykos Therapeutics MDMA-assisted therapy, and the chances of it passing. He firmly believes if approved by the FDA, with a slated time period of early August, that would we could see the following .. “I think you could see a market move unlike anything for an industry throughout public markets history” Does it seem bold? Well think about what’s happened this year. atai Life Sciences $50m investment into Beckley Psytech. Cybin Inc raising $150m with a number of strategic biotech investors. MindMed and the $175m they raised after their ground breaking phase 2 results. Reunion Neuroscience raising $103m. Not to mention, Lykos raised $100m back in January. If approved, you’re only going to see the valuation of this company increase dramatically. Check our latest podcast in the comment section. Doug Drysdale Robert Barrow Payton Nyquvest Cosmo Feilding Mellen Florian Brand Christian Angermayer Lars Christian Wilde E. Matthew ("Whiz") Buckley Elemer Piros Daniel Carcillo Joe Caltabiano Rob Crocker Graham Farrell Michael Boughner Tyler Beuerlein Michael Tan Rick Doblin Michael B. Galloro, CPA Barrington Miller #psychedelics #psychedelic #psychedelicstocks #mentalhealth #stocks

Latest DON Monte Carlo news. Attention all sophisticated investors. OmniSpirant Limited are delighted to announce the granting of a Venture and Innovation Award by the UK Cystic Fibrosis Trust. OmniSpirant is currently raising funds to expand and continue to develop RNA therapeutics for diseases with high unmet medical needs. Our financial model forecasts the need to raise €80M alongside our existing non-dilutive funding to reach clinical stages and generate meaningful clinical readouts for our oncology (OS003) and ARDS (OS006) programs, both of which have potential for accelerated market approval. The funding will also be used to expand our identified pipeline (4 further programs, each capable of disrupting and expanding existing multi-billion markets), and for the scalable GMP translation of our OmniSome manufacturing process. Our versatile platform can be applied to realize significant revenues from licensing deals within the investment runway. To speak with the CEO Gerry McCauley about this opportunity please book a sophisticated investor call via this link - https://lnkd.in/ejrueCpc #biotechnology #rnatherapeutics #fundingopportunity #investing

**Artiva Biotech Prices $167M IPO, Riding Optimism for Autoimmune Cell Therapy** ===================================================== Artiva Biotech, a biotech company focused on autoimmune cell therapies, has priced its initial public offering (IPO) of 10 million shares at $16.70 per share, raising $167 million. The company will use the funds to advance its lead program, ART-820, an allogeneic autoimmune cell therapy for the treatment of multiple sclerosis. The IPO comes amid growing optimism for autoimmune cell therapies, with several companies in the space seeing significant success in clinical trials. **#Biotech #IPO #Autoimmune #CellTherapy** Source: https://lnkd.in/gexSHD9k Update Date: 1 day ago

It's no secret that I'm a big believer that #biotech is the investment wave of the 2020s. So, am I surprised that CG Oncology's IPO soared by 96% on its first day? Well, a little! Some #investors have been slow to adopt the biotech wave—especially when it's a brand-new IPO. But CG's success could point to increased (and much-deserved) interest in the field. Time will tell if CG Oncology can live up to these expectations. But one thing is clear: biotech #investments are growing in popularity. And I expect that trend to continue for at least the next several years. https://loom.ly/GNf7vvQ

Boundless Bio, a startup in the clinic with two small molecules for cancer, priced its $100 million IPO Wednesday night and will start trading as $BOLD on Thursday morning. The Nasdaq debut comes 10 months after it disclosed a Series C of the same size. Its bell ringing in Times Square will likely be followed by a fellow clinical-stage San Diego biotech, as J&J-partnered Contineum Therapeutics has also outlined plans for an IPO. Boundless sought an IPO as early as last fall, with an SEC filing from Sept. 1 indicating it could seek a 2023 listing. “We’re thinking about this as a fourth revolution in cancer therapies,” CEO Zachary Hornby told Endpoints News when the company unveiled in 2019. Chemotherapy, targeted medicines and immunotherapy were the first three, by his telling. Prolific life sciences investor and incubator ARCH Venture Partners formed the biotech a little over five years ago to go after extrachromosomal DNA. #biotech #bold #nasdaq #ipo #initialpublicoffering #drugdevelopment #cancerresearch

Scailyte Extends Series A to USD 8 Million! We are thrilled to announce the extension of our Series A funding, bringing the total raised amount to USD 8 million. Accelerating Innovation and Expanding Horizons These additional resources will play a pivotal role in accelerating Scailyte's impact in the immuno-oncology landscape, expanding our business partnerships and market footprint. We are committed to solidifying our position as a leading biomarker discovery and translational platform harnessing the power of single-cell omics and proprietary AI algorithms. Peter Nestorov, CEO and co-founder, shares his excitement, "In the past year, we have gained significant commercial traction, validating the market need for an unbiased and powerful biomarker discovery approach, which delivers reliable and translatable insights from small patient populations. With the newly raised funds, we will expand our presence in the US market, seeking further partnerships with like-minded biotech and pharma companies in the precision oncology space." Pascal Koenig, Chair of the Board of Directors, comments, "This additional investment is a testament to the long-term trust and recognition of Scailyte's potential and tireless efforts. It reaffirms our commitment to advancing the field of precision oncology." Thank you for your unwavering support on our journey to transform oncology research. Together, we're making a difference! #SeriesA #Biotech #BiomarkerDiscovery #PrecisionOncology #Innovation

BillionToOne, a pioneering molecular diagnostics company, has announced a successful Series D funding round, raising $130 million. The oversubscribed round was led by Premji Invest, with substantial contributions from new investor Neuberger Berman and existing investors such as Adam Street Partners, Baillie Gifford, Hummingbird Ventures, Civilization Ventures, Libertus Capital, and Fifty Years. This significant influx of capital will be utilized to expand and scale BillionToOne’s prenatal screening and oncology diagnostics businesses. BillionToOne’s cutting-edge technology, Quantitative Counting Templates™ (QCTs™), enables the precise counting of DNA molecules at the single base-pair level. This innovation has allowed the company to develop unique and differentiated tests that push the boundaries of molecular diagnostics. To date, over half a million patients have benefited from BillionToOne’s tests, and the company has seen remarkable growth, achieving an annual recurring revenue of $125 million in just four years. Read more: https://lnkd.in/dB74aWEv